Reply Shapes the Future of Autonomous Mobile Robots with the Power of Microsoft Azure
6.7.2021 10:30:00 EEST | Business Wire | Press release
Reply announced today that it has developed an end-to-end solution architecture for autonomous mobile robots (AMR) on Microsoft Azure that enables new business applications across industries, reduces upfront costs and allows for the rapid implementation of customer-specific robotics use cases.
The solution combines Microsoft Azure services, the agility of Boston Dynamics' SPOT and Reply’s knowledge of intelligent cloud computing services, edge computing and artificial intelligence. To demonstrate the capabilities of a scalable and versatile robotics platform, Reply implemented an automated vehicle-damage-detection solution for rental or leasing companies that leverages this architecture. In fact, rental or leasing companies must inspect vehicles for any damage after they are returned in order to ensure the safety and quality of their fleet for their customers. This is usually done in the time- and cost-consuming manual process of walking around the car, visually inspecting it, assessing the severity of the damage and conducting a damage report.
Reply integrates Azure Cognitive Services, Machine Learning and DevOps as well as Power Apps and Power BI. Thanks to Azure's intelligent service foundation, agile workflows and machine learning, this process can be fully automated. Using computer vision, SPOT moves freely through the parking area and scans the license plates to find the right vehicle. Once detected, it walks around the vehicle to record its condition by continuously collecting visual data with its camera and sensors. This information is processed “on the edge” or transmitted to the cloud, where advanced image recognition and machine leaning algorithms perform the damage detection. All detected damages are saved in the return protocol, and they can be presented to the customer and the fleet manager for approval.
“This platform sets the power of Microsoft Azure on the move by bringing it from the Cloud to the Edge and into highly advanced mobile robotic devices, giving them the autonomy to unlock novel business use cases. Thanks to the agile reference architecture, we are able to implement customer-specific use cases in various industries that include all types of mobile robots or drones”, comments Filippo Rizzante, CTO Reply.
“Reply is a long-term, trusted partner in delivering Azure IoT solutions, and we’re delighted to continue our collaboration on this new scalable robotics offering. By leveraging Microsoft Azure, we can help accelerate this transformation by making it easier for businesses to bring AI and analytics capabilities to these autonomous systems in a consistent and secure way,” adds Lakecia Gunter, Vice President and GM, Global IOT Channel at Microsoft.
With their agility, autonomous mobile robots (AMR) are able to move independently from a central infrastructure on terrain that is not traditionally designed for robots. They can be used in hazardous environments and environments, that are harmful to people. According to ResearchAndMarkets.com, the global market for automated guided vehicle (AGV) and AMR is expected to reach $13.2 Billion by 2026 with a growth rate of around 35%. Both AGVs and AMRs collectively are going to cross the installed base of 1.5 Million in the next 5 years to make mobile robots a new normal in our day-to-day operational activities.
Reply
Reply [MTA, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com
Source Global Mobile Robots (AGV & AMR) Market:
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210706005133/en/
Contact information
Media
Reply
Fabio Zappelli
f.zappelli@reply.com
Tel. +390117711594
Sandra Dennhardt
s.dennhardt@reply.com
+49 170 454 62 29
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom